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Group O red blood cells in 
massive transfusion—when to 
pull the switch?
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Using uncrossmatched group O RBCs is common 
practice in the management of patients requiring 
urgent transfusion.  The standard dicta are that one 
should determine the native patient type as soon as 
possible and then switch back to that type for fur-
ther transfusion.  Given that group O RBCs contain 
a quantity of residual plasma and donor isoaggluti-
nins and that the patient’s actual blood type once 
determined may be other than group O, clinically 
significant hemolysis (or other immune-mediated 
sequelae) after such a switch is a natural concern. 
Hence, most massive transfusion protocols mandate 
continued use of group O RBCs once a threshold 
number of units has been given.  Unfortunately, the 
need for such a threshold or even what it should be 
remains unclear as there are no data contrasting the 
effects of different thresholds on RBC destruction or 
survival in the recipient or on patient outcome.
The literature regarding the ill effects of incom-
patible plasma attributable to RBC transfusion is 
fairly old and predates the use of additive solutions. 
Two papers1,2 report the safety and efficacy of un-
crossmatched group O RBCs in a trauma setting and 
suggest a threshold number of units.  The number of 
patients receiving massive transfusion was small in 
each case; the recommendations were made as a result 
of serologic testing (e.g., higher frequency of a positive 
antiglobulin test in more heavily transfused patients) 
and were not outcome based.  Given the methods and 
statistics, this literature is not sufficient to establish 
either the absolute safety of a lesser number of units 
or, conversely, the danger of a greater number.
Because no substantiated threshold value exists, 
practice is necessarily arbitrary.  Although no sur-
vey regarding such practice has been published, it 
likely varies considerably.  In fact, a perusal of the 
California Blood Bank Society e-network forum, an 
electronic discussion board, demonstrates, albeit 
not rigorously, both this variability and a desire on 
the part of transfusionists for rational guidance.3–5 
Fortunately, although data specific to RBC transfu-
sion may be absent, there may in fact be enough 
evidence available in the literature regarding the ef-
fects of incompatible plasma in the setting of platelet 
transfusion to allow a reasonable, if not conclusive, 
inference.
A recent review of this literature and survey of 
practices in 3156 laboratories summarized the avail-
able case reports.6  Brisk hemolysis occurred in a 
small subset of patients (more often group A) receiv-
ing group O platelets; in some cases this hemolysis 
was associated with a poor clinical outcome.  Not 
surprisingly, pediatric patients appear to be more at 
risk, and the majority of the reports involve apheresis 
platelets, in which a significant volume of plasma 
(approximately 145 to 448 mL, equivalent to the 
volume of plasma in 5 to 15 additive RBC units) con-
taining a potent high-titer antibody is obtained from 
the same donor.6  A study evaluating the changes 
in hemoglobin in recipients of plasma-incompatible 
apheresis platelets found no appreciable hemolysis, 
consistent with the general belief that most patients 
receiving such components do not routinely suffer 
adverse effects.7
Interestingly, despite these substantial available 
data, including documentation of in vivo hemolysis 
in occasional patients, Fung et al.6 reported quite di-
verse strategies and policies for adult patients in the 
laboratories they surveyed.  Only a small minority 
(9.9%) reported having a formal policy identifying a 
threshold volume or threshold volume per unit time 
for the infusion of incompatible plasma.
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Hemolysis in the setting of a smaller donor-plas-
ma dose (RBC or whole blood-derived platelets) is 
far rarer, although there are reports in the literature. 
Brisk hemolysis apparently occurred in a Brazilian 
patient who received a single unit of group O RBC 
(55 mL of plasma), with an anti-A1 titer of 1024 (AHG, 
saline).8  The donor’s RBCs had previously been 
transfused to a group A recipient without incident. 
In another case report, transfusion of 50 to 70 mL 
of whole blood-derived platelets containing a very 
high titer (16,000 AHG) anti-B resulted in hemolysis 
of 40 percent of the adult recipient’s circulating RBC 
mass.9  Two other case reports of pooled platelets 
causing brisk hemolysis are also interesting.10,11  The 
doses were four group O platelet units with a total 
volume transfused of 60 to 80 mL (anti-A1 titers of 
64 and 128 available for two units only [AHG]), and 
10 platelet units (500 mL), with a pooled anti-A titer 
of 256 (AHG).  In both cases the patient possessed a 
subgroup of A, presumably limiting the absorption 
of antibody by native cells and tissues to anti-A and 
rendering transfused A1 RBCs more vulnerable.
The risk of a hemolytic reaction per unit of 
plasma-incompatible apheresis platelets has been 
calculated to be anywhere from 1 in 6600 to 1 in 
9000.7,12  Clearly such calculations are empiric and 
fraught with potential error, as less overt or unde-
tected hemolysis may occur, and some patients may 
be more at risk than others.  Nonetheless, these are 
fairly small numbers when one considers that a titer 
of anti-A or anti-B high enough to be considered 
“dangerous” (16–600) is present in 10 to 20 percent 
of group O blood donors (various reports, AHG and 
saline).12  It seems likely that, although a high titer 
may be a prerequisite for trouble, there may be other 
aggravating factors that are important as well.
The notion of occasional “dangerous donors” 
with exceptionally potent antibodies is not a new 
one, and based on the handful of reports of serious 
hemolysis even with a small dose of plasma from 
such donors, it appears that no dose of incompatible 
plasma can automatically be assumed to be safe.  In 
fact, one could argue that the use of group O RBCs in 
non-group O patients presents risk in the first place. 
Only with testing for high-titer antibodies (as is done 
in the United Kingdom) can this small but nonzero 
risk be removed.
In any case, the available evidence supports the 
model that as with platelets, hemolysis after the 
switch back to RBC of the patient’s native type would 
arise from the rare exposure to plasma from a “dan-
gerous” donor as opposed to cumulative acquisition 
of low-titer antibody from multiple donors.  Although 
a greater number of donors theoretically increases 
the very small risk of encountering such a donor, it 
does so to a very small degree.  In fact, Fung et al.6 
comment in their discussion that such an approach 
may stop passive accumulation of low-titer antibody 
from multiple donors but fails to prevent the infusion 
of high-titer antibody from a single donor.  Hence as 
with platelet transfusion, for which most laboratories 
have not established volume limits for incompatible 
plasma, there is likely to be little benefit to these 
limits for RBCs.
Thus, one can fairly argue that the risk inherent 
to receiving incompatible plasma is inappreciably 
affected by the number of RBC units transfused and 
that based on the available evidence it is acceptable 
practice to switch back to the patient’s native type 
regardless of that number.  If an arbitrary thresh-
old is used, it should be consistent with the limit(s) 
imposed on other sources of incompatible plasma. 
These include apheresis platelets and testing of 
posttransfusion isoagglutinin titers, which should be 
considered, as these will be low most of the time and 
would obviate the need to honor the threshold.  In 
the setting of chronic shortages, in which one must 
eliminate or significantly reduce unnecessary use 
of blood, there is a need to triage scarce resources 
rationally.  Therefore, even those institutions using 
a threshold should consider relaxing it to address 
critically low supplies of group O RBCs.
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